Trial Profile
Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides Or Sezary Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 06 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 06 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 18 Aug 2019.